Holen Sie sich die Stockscreener-App
1.68
2.33%
-0.04
Handel nachbörslich:
1.67
-0.01
-0.60%
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
ADC Therapeutics SA (NYSE:ADCT) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - BioSpace
ADC Therapeutics Takes Center Stage: Key Investor Presentation Coming at Major Biotech Conference - StockTitan
ADCT stock touches 52-week low at $1.66 amid market challenges - MSN
Brokers Set Expectations for ADCT FY2025 Earnings - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Expands By 18.0% - MarketBeat
Barclays PLC Raises Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA Reveals Preliminary ZYNLONTA Net Sales Information in Recent Corporate Presentation - Defense World
Institutional owners may consider drastic measures as ADC Therapeutics SA's (NYSE:ADCT) recent US$21m drop adds to long-term losses - Simply Wall St
Jane Street Group LLC Buys 38,859 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics : JP Morgan 43rd Annual Healthcare Conference - Marketscreener.com
Geode Capital Management LLC Buys 128,454 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics (NYSE:ADCT) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates "Buy" Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
Barclays PLC Buys 93,890 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - IT News Online
Is ADC Therapeutics SA (NYSE:ADCT) Worth US$2.0 Based On Its Intrinsic Value? - Yahoo Finance
ADC Therapeutics Grants Inducement Stock Options to New Employees in Retention Push | ADCT Stock News - StockTitan
ADC spikes after enrollment update on confirmatory trial for lymphoma therapy - MSN
ADC Therapeutics stock rises on enrollment update (ADCT:NYSE) - Seeking Alpha
ADC Therapeutics SA (NYSE:ADCT) Shares Purchased by State Street Corp - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Rises By 36.9% - MarketBeat
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma - PR Newswire
ADC Therapeutics Completes Enrollment in Pivotal ZYNLONTA Lymphoma Trial with 80% Response Rate - StockTitan
Fmr LLC Takes $167,000 Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Charles Schwab Investment Management Inc. Acquires 18,796 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Top 10 Companies to Watch Out for in Antibody Drug Conjugates - openPR
ADC Therapeutics' SWOT analysis: zynlonta sales challenges offset by expansion hopes - Investing.com
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development - Yahoo Finance UK
Redmile Group, Llc Acquires 100,000 Shares of ADC Therapeutics SA (NYSE:ADCT) Stock - MarketBeat
Research Analysts Issue Forecasts for ADCT FY2024 Earnings - Defense World
Redmile Group, LLC Increases Stake in ADC Therapeutics SA - GuruFocus.com
FY2024 Earnings Estimate for ADCT Issued By HC Wainwright - MarketBeat
Guggenheim Reaffirms “Buy” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
Adc therapeutics sees $609,000 in stock purchases by Redmile - Investing.com South Africa
ADC Therapeutics stock plunges 36% amid Zynlonta data release - MSN
HC Wainwright Reiterates “Buy” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics stock plunges 36% amid Zynlonta data release (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics shares drop after trial results By Investing.com - Investing.com South Africa
ADC Therapeutics shares drop after trial results - Investing.com
Adc Therapeutics Sa Announces Positive Initial Data from Lotis-7 Clinical Trial Evaluating Zynlonta®? in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Marketscreener.com
ADC Teeters on Trial Data - Baystreet.ca
ADC Therapeutics SA Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA®? in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Marketscreener.com
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Nasdaq
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma - Quantisnow
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial - Marketscreener.com
Adc Therapeutics Sa Announces the Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating Zynlonta®? in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma - Marketscreener.com
Insider Selling: ADC Therapeutics SA (NYSE:ADCT) Major Shareholder Sells 25,352 Shares of Stock - MarketBeat
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):